[424B5] Rein Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Rein Therapeutics (Nasdaq: RNTX) filed a Rule 424(b)(5) prospectus supplement that amends its May 22 2025 at-the-market (ATM) shelf with H.C. Wainwright.
The filing reduces the remaining issuance capacity under the Form S-3 from $15.77 million to $8.07 million. The cut aligns with General Instruction I.B.6, which limits sales to one-third of the company鈥檚 $42.3 million public float (calculated on July 24 2025) during any 12-month period while the float remains below $75 million.
To date the company has raised only $35,460 (16,127 shares) through the ATM. Following the adjustment, up to approximately $8.03 million of common stock can still be issued from time to time. Additional supplements will be required if a larger float later permits greater issuance capacity.
RNTX shares last closed at $1.41 on July 28 2025. Investors should evaluate the dilution risk associated with future ATM sales versus the financing flexibility this mechanism provides.
Rein Therapeutics (Nasdaq: RNTX) ha depositato un supplemento al prospetto Rule 424(b)(5) che modifica la sua linea di emissione at-the-market (ATM) con H.C. Wainwright, originariamente prevista per il 22 maggio 2025.
Il deposito riduce la capacit脿 residua di emissione sotto il modulo S-3 da 15,77 milioni di dollari a 8,07 milioni di dollari. Questa riduzione 猫 conforme all'Istruzione Generale I.B.6, che limita le vendite a un terzo della flottante pubblica della societ脿 di 42,3 milioni di dollari (calcolata al 24 luglio 2025) durante un periodo di 12 mesi, fintanto che la flottante rimane sotto i 75 milioni di dollari.
Ad oggi la societ脿 ha raccolto solo 35.460 dollari (16.127 azioni) tramite l鈥橝TM. Dopo questa modifica, potr脿 ancora emettere azioni ordinarie per un valore fino a circa 8,03 milioni di dollari di volta in volta. Saranno necessari ulteriori supplementi se in futuro una flottante pi霉 ampia consentir脿 una maggiore capacit脿 di emissione.
Le azioni RNTX hanno chiuso l鈥檜ltima volta a 1,41 dollari il 28 luglio 2025. Gli investitori dovrebbero valutare il rischio di diluizione associato a future vendite ATM rispetto alla flessibilit脿 di finanziamento che questo meccanismo offre.
Rein Therapeutics (Nasdaq: RNTX) present贸 un suplemento al prospecto Rule 424(b)(5) que modifica su l铆nea de emisi贸n at-the-market (ATM) con H.C. Wainwright, originalmente establecida para el 22 de mayo de 2025.
La presentaci贸n reduce la capacidad restante de emisi贸n bajo el Formulario S-3 de 15,77 millones de d贸lares a 8,07 millones de d贸lares. Esta reducci贸n cumple con la Instrucci贸n General I.B.6, que limita las ventas a un tercio del float p煤blico de la compa帽铆a de 42,3 millones de d贸lares (calculado al 24 de julio de 2025) durante cualquier per铆odo de 12 meses mientras el float permanezca por debajo de 75 millones de d贸lares.
Hasta la fecha, la compa帽铆a ha recaudado solo 35,460 d贸lares (16,127 acciones) a trav茅s del ATM. Tras este ajuste, a煤n podr谩 emitir acciones comunes por un valor aproximado de 8,03 millones de d贸lares de forma ocasional. Se requerir谩n suplementos adicionales si un float mayor permite posteriormente una mayor capacidad de emisi贸n.
Las acciones de RNTX cerraron por 煤ltima vez a 1,41 d贸lares el 28 de julio de 2025. Los inversores deben evaluar el riesgo de diluci贸n asociado con futuras ventas ATM frente a la flexibilidad financiera que este mecanismo proporciona.
Rein Therapeutics (雮橃姢雼�: RNTX)電� 2025雲� 5鞗� 22鞚检棎 鞓堨爼霅� H.C. Wainwright鞕�鞚� 鞁滌灔臧� 氚滍枆(ATM) 靺疙攧毳� 靾橃爼頃橂姅 Rule 424(b)(5) 氤挫订 靹る獏靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.
鞚措矆 鞝滌稖鞚� Form S-3鞐� 霐半ジ 雮潃 氚滍枆 頃滊弰毳� 1,577毵� 雼煬鞐愳劀 807毵� 雼煬搿� 臧愳唽鞁滌及鞀惦媹雼�. 鞚� 臁办爼鞚� 2025雲� 7鞗� 24鞚� 旮办鞙茧 須岇偓鞚� 4,230毵� 雼煬 瓿惦欤检嫕靾橃潣 3攵勳潣 1搿� 韺愲Г毳� 鞝滍暅頃橂姅 鞚茧皹 歆�旃� I.B.6鞐� 攵�頃╉晿氅�, 瓿惦欤检嫕靾橁皜 7,500毵� 雼煬 氙鸽鞚� 霃欖晥 12臧滌洈 旮瓣皠 雮挫棎 鞝侅毄霅╇媹雼�.
順勳灛旯岇 須岇偓電� ATM鞚� 韱淀暣 雼 35,460雼煬(16,127欤�)毵岇潉 臁半嫭頄堨姷雼堧嫟. 鞚措矆 臁办爼 頉勳棎霃� 鞎� 803毵� 雼煬 靸侂嫻鞚� 氤错喌欤茧ゼ 靾橃嫓搿� 氚滍枆頃� 靾� 鞛堨姷雼堧嫟. 毵岇暯 瓿惦欤检嫕靾橁皜 歃濌皜頃橃棳 雿� 韥� 氚滍枆 頃滊弰臧� 項堨毄霅橂┐ 於旉皜 氤挫订 靹る獏靹滉皜 頃勳殧頃╇媹雼�.
RNTX 欤缄皜電� 2025雲� 7鞗� 28鞚� 毵堨毵夓溂搿� 1.41雼煬鞐� 毵堦皭霅橃棃鞀惦媹雼�. 韴瀽鞛愲摛鞚� 頄ロ泟 ATM 韺愲Г鞐� 霐半ジ 頋劃 鞙勴棙瓿� 鞚� 氅旍护雼堨鞚� 鞝滉车頃橂姅 鞛愱笀 臁半嫭 鞙犾棸靹膘潉 鞁犾頌� 韽夑皜頃挫暭 頃╇媹雼�.
Rein Therapeutics (Nasdaq : RNTX) a d茅pos茅 un suppl茅ment au prospectus Rule 424(b)(5) modifiant sa ligne d鈥櫭﹎ission at-the-market (ATM) avec H.C. Wainwright, initialement pr茅vue pour le 22 mai 2025.
Le d茅p么t r茅duit la capacit茅 d鈥櫭﹎ission restante sous le formulaire S-3 de 15,77 millions de dollars 脿 8,07 millions de dollars. Cette r茅duction est conforme 脿 l鈥橧nstruction G茅n茅rale I.B.6, qui limite les ventes 脿 un tiers du flottant public de la soci茅t茅 de 42,3 millions de dollars (calcul茅 au 24 juillet 2025) sur une p茅riode de 12 mois tant que le flottant reste inf茅rieur 脿 75 millions de dollars.
脌 ce jour, la soci茅t茅 n鈥檃 lev茅 que 35 460 dollars (16 127 actions) via l鈥橝TM. Apr猫s cet ajustement, elle pourra encore 茅mettre des actions ordinaires pour un montant d鈥檈nviron 8,03 millions de dollars de temps 脿 autre. D鈥檃utres suppl茅ments seront n茅cessaires si un flottant plus important permet ult茅rieurement une capacit茅 d鈥櫭﹎ission accrue.
Les actions RNTX ont cl么tur茅 脿 1,41 dollar le 28 juillet 2025. Les investisseurs doivent 茅valuer le risque de dilution li茅 aux futures ventes ATM par rapport 脿 la flexibilit茅 de financement que ce m茅canisme offre.
Rein Therapeutics (Nasdaq: RNTX) hat einen Rule 424(b)(5) Prospekterg盲nzung eingereicht, der das At-the-Market (ATM) Shelf mit H.C. Wainwright vom 22. Mai 2025 盲ndert.
Die Einreichung reduziert die verbleibende Emissionskapazit盲t unter dem Formular S-3 von 15,77 Millionen US-Dollar auf 8,07 Millionen US-Dollar. Diese K眉rzung entspricht der Allgemeinen Anweisung I.B.6, die Verk盲ufe auf ein Drittel des 枚ffentlichen Streubesitzes des Unternehmens von 42,3 Millionen US-Dollar (berechnet am 24. Juli 2025) innerhalb eines 12-Monats-Zeitraums begrenzt, solange der Streubesitz unter 75 Millionen US-Dollar bleibt.
Bisher hat das Unternehmen nur 35.460 US-Dollar (16.127 Aktien) 眉ber das ATM aufgenommen. Nach der Anpassung k枚nnen weiterhin bis zu etwa 8,03 Millionen US-Dollar an Stammaktien von Zeit zu Zeit ausgegeben werden. Weitere Erg盲nzungen sind erforderlich, falls ein gr枚脽erer Streubesitz sp盲ter eine h枚here Emissionskapazit盲t erlaubt.
Die RNTX-Aktien schlossen zuletzt am 28. Juli 2025 bei 1,41 US-Dollar. Anleger sollten das 痴别谤飞盲蝉蝉别谤耻苍驳蝉谤颈蝉颈办辞 k眉nftiger ATM-Verk盲ufe gegen die Finanzierungsm枚glichkeiten abw盲gen, die dieser Mechanismus bietet.
- Maintains ~$8.07 m ATM capacity, providing flexible, quick-access financing without underwriting fees.
- Filing keeps the shelf fully compliant with SEC Form S-3 limits, avoiding potential registration issues.
- Potential dilution of up to 19% of current market cap if full $8 m is issued at recent prices.
- Reduced capacity from $15.77 m highlights limited public float and micro-cap status, potentially restricting longer-term funding options.
Insights
TL;DR: Neutral鈥攃apacity cut reflects regulatory cap, modest dilution risk, improves compliance.
The supplement simply aligns the ATM program with the one-third public-float restriction applicable to micro-caps. Only $35k has been raised so far, so near-term dilution is minimal. However, authorizing up to $8 m (鈮�19% of market cap) leaves open incremental dilution at market prices that have drifted to $1.41. The action signals continued reliance on equity financing, but also shows management is maintaining registration-statement compliance. Overall financial impact is limited today; future effect depends on usage pace and pricing.
TL;DR: Procedural adjustment; keeps ATM valid, liquidity optionality intact.
The downsizing is mechanical under Form S-3 rules, not a strategic reversal. By preserving ~$8 m of shelf room, the company secures flexible, low-cost capital for working capital or R&D without renegotiating new agreements. Yet, given sub-$75 m float, any sizable draw will meaningfully dilute holders. Investors should watch trading volumes and subsequent 424(b)(5) filings for execution pace; heavy usage during price weakness could pressure shares.
Rein Therapeutics (Nasdaq: RNTX) ha depositato un supplemento al prospetto Rule 424(b)(5) che modifica la sua linea di emissione at-the-market (ATM) con H.C. Wainwright, originariamente prevista per il 22 maggio 2025.
Il deposito riduce la capacit脿 residua di emissione sotto il modulo S-3 da 15,77 milioni di dollari a 8,07 milioni di dollari. Questa riduzione 猫 conforme all'Istruzione Generale I.B.6, che limita le vendite a un terzo della flottante pubblica della societ脿 di 42,3 milioni di dollari (calcolata al 24 luglio 2025) durante un periodo di 12 mesi, fintanto che la flottante rimane sotto i 75 milioni di dollari.
Ad oggi la societ脿 ha raccolto solo 35.460 dollari (16.127 azioni) tramite l鈥橝TM. Dopo questa modifica, potr脿 ancora emettere azioni ordinarie per un valore fino a circa 8,03 milioni di dollari di volta in volta. Saranno necessari ulteriori supplementi se in futuro una flottante pi霉 ampia consentir脿 una maggiore capacit脿 di emissione.
Le azioni RNTX hanno chiuso l鈥檜ltima volta a 1,41 dollari il 28 luglio 2025. Gli investitori dovrebbero valutare il rischio di diluizione associato a future vendite ATM rispetto alla flessibilit脿 di finanziamento che questo meccanismo offre.
Rein Therapeutics (Nasdaq: RNTX) present贸 un suplemento al prospecto Rule 424(b)(5) que modifica su l铆nea de emisi贸n at-the-market (ATM) con H.C. Wainwright, originalmente establecida para el 22 de mayo de 2025.
La presentaci贸n reduce la capacidad restante de emisi贸n bajo el Formulario S-3 de 15,77 millones de d贸lares a 8,07 millones de d贸lares. Esta reducci贸n cumple con la Instrucci贸n General I.B.6, que limita las ventas a un tercio del float p煤blico de la compa帽铆a de 42,3 millones de d贸lares (calculado al 24 de julio de 2025) durante cualquier per铆odo de 12 meses mientras el float permanezca por debajo de 75 millones de d贸lares.
Hasta la fecha, la compa帽铆a ha recaudado solo 35,460 d贸lares (16,127 acciones) a trav茅s del ATM. Tras este ajuste, a煤n podr谩 emitir acciones comunes por un valor aproximado de 8,03 millones de d贸lares de forma ocasional. Se requerir谩n suplementos adicionales si un float mayor permite posteriormente una mayor capacidad de emisi贸n.
Las acciones de RNTX cerraron por 煤ltima vez a 1,41 d贸lares el 28 de julio de 2025. Los inversores deben evaluar el riesgo de diluci贸n asociado con futuras ventas ATM frente a la flexibilidad financiera que este mecanismo proporciona.
Rein Therapeutics (雮橃姢雼�: RNTX)電� 2025雲� 5鞗� 22鞚检棎 鞓堨爼霅� H.C. Wainwright鞕�鞚� 鞁滌灔臧� 氚滍枆(ATM) 靺疙攧毳� 靾橃爼頃橂姅 Rule 424(b)(5) 氤挫订 靹る獏靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.
鞚措矆 鞝滌稖鞚� Form S-3鞐� 霐半ジ 雮潃 氚滍枆 頃滊弰毳� 1,577毵� 雼煬鞐愳劀 807毵� 雼煬搿� 臧愳唽鞁滌及鞀惦媹雼�. 鞚� 臁办爼鞚� 2025雲� 7鞗� 24鞚� 旮办鞙茧 須岇偓鞚� 4,230毵� 雼煬 瓿惦欤检嫕靾橃潣 3攵勳潣 1搿� 韺愲Г毳� 鞝滍暅頃橂姅 鞚茧皹 歆�旃� I.B.6鞐� 攵�頃╉晿氅�, 瓿惦欤检嫕靾橁皜 7,500毵� 雼煬 氙鸽鞚� 霃欖晥 12臧滌洈 旮瓣皠 雮挫棎 鞝侅毄霅╇媹雼�.
順勳灛旯岇 須岇偓電� ATM鞚� 韱淀暣 雼 35,460雼煬(16,127欤�)毵岇潉 臁半嫭頄堨姷雼堧嫟. 鞚措矆 臁办爼 頉勳棎霃� 鞎� 803毵� 雼煬 靸侂嫻鞚� 氤错喌欤茧ゼ 靾橃嫓搿� 氚滍枆頃� 靾� 鞛堨姷雼堧嫟. 毵岇暯 瓿惦欤检嫕靾橁皜 歃濌皜頃橃棳 雿� 韥� 氚滍枆 頃滊弰臧� 項堨毄霅橂┐ 於旉皜 氤挫订 靹る獏靹滉皜 頃勳殧頃╇媹雼�.
RNTX 欤缄皜電� 2025雲� 7鞗� 28鞚� 毵堨毵夓溂搿� 1.41雼煬鞐� 毵堦皭霅橃棃鞀惦媹雼�. 韴瀽鞛愲摛鞚� 頄ロ泟 ATM 韺愲Г鞐� 霐半ジ 頋劃 鞙勴棙瓿� 鞚� 氅旍护雼堨鞚� 鞝滉车頃橂姅 鞛愱笀 臁半嫭 鞙犾棸靹膘潉 鞁犾頌� 韽夑皜頃挫暭 頃╇媹雼�.
Rein Therapeutics (Nasdaq : RNTX) a d茅pos茅 un suppl茅ment au prospectus Rule 424(b)(5) modifiant sa ligne d鈥櫭﹎ission at-the-market (ATM) avec H.C. Wainwright, initialement pr茅vue pour le 22 mai 2025.
Le d茅p么t r茅duit la capacit茅 d鈥櫭﹎ission restante sous le formulaire S-3 de 15,77 millions de dollars 脿 8,07 millions de dollars. Cette r茅duction est conforme 脿 l鈥橧nstruction G茅n茅rale I.B.6, qui limite les ventes 脿 un tiers du flottant public de la soci茅t茅 de 42,3 millions de dollars (calcul茅 au 24 juillet 2025) sur une p茅riode de 12 mois tant que le flottant reste inf茅rieur 脿 75 millions de dollars.
脌 ce jour, la soci茅t茅 n鈥檃 lev茅 que 35 460 dollars (16 127 actions) via l鈥橝TM. Apr猫s cet ajustement, elle pourra encore 茅mettre des actions ordinaires pour un montant d鈥檈nviron 8,03 millions de dollars de temps 脿 autre. D鈥檃utres suppl茅ments seront n茅cessaires si un flottant plus important permet ult茅rieurement une capacit茅 d鈥櫭﹎ission accrue.
Les actions RNTX ont cl么tur茅 脿 1,41 dollar le 28 juillet 2025. Les investisseurs doivent 茅valuer le risque de dilution li茅 aux futures ventes ATM par rapport 脿 la flexibilit茅 de financement que ce m茅canisme offre.
Rein Therapeutics (Nasdaq: RNTX) hat einen Rule 424(b)(5) Prospekterg盲nzung eingereicht, der das At-the-Market (ATM) Shelf mit H.C. Wainwright vom 22. Mai 2025 盲ndert.
Die Einreichung reduziert die verbleibende Emissionskapazit盲t unter dem Formular S-3 von 15,77 Millionen US-Dollar auf 8,07 Millionen US-Dollar. Diese K眉rzung entspricht der Allgemeinen Anweisung I.B.6, die Verk盲ufe auf ein Drittel des 枚ffentlichen Streubesitzes des Unternehmens von 42,3 Millionen US-Dollar (berechnet am 24. Juli 2025) innerhalb eines 12-Monats-Zeitraums begrenzt, solange der Streubesitz unter 75 Millionen US-Dollar bleibt.
Bisher hat das Unternehmen nur 35.460 US-Dollar (16.127 Aktien) 眉ber das ATM aufgenommen. Nach der Anpassung k枚nnen weiterhin bis zu etwa 8,03 Millionen US-Dollar an Stammaktien von Zeit zu Zeit ausgegeben werden. Weitere Erg盲nzungen sind erforderlich, falls ein gr枚脽erer Streubesitz sp盲ter eine h枚here Emissionskapazit盲t erlaubt.
Die RNTX-Aktien schlossen zuletzt am 28. Juli 2025 bei 1,41 US-Dollar. Anleger sollten das 痴别谤飞盲蝉蝉别谤耻苍驳蝉谤颈蝉颈办辞 k眉nftiger ATM-Verk盲ufe gegen die Finanzierungsm枚glichkeiten abw盲gen, die dieser Mechanismus bietet.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-287342
PROSPECTUS SUPPLEMENT
(To Prospectus dated May 22, 2025)
$8,066,607
Common Stock
This prospectus supplement amends and supplements certain information in the prospectus, dated May 22, 2025, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-287342), which we refer to as the Prior Prospectus, relating to the offer and sale of shares of our common stock, $0.001 par value per share, having an aggregate offering price of up to $15,773,673 pursuant to the At the Market Offering Agreement, dated May 15, 2025, or the sales agreement, that we previously entered into with H.C. Wainwright & Co., LLC. As of the date of this prospectus supplement, we had sold an aggregate of 16,127 shares of our common stock in accordance with the sales agreement under the Prior Prospectus for aggregate gross proceeds of $35,460. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.
We are filing this prospectus supplement to amend the Prior Prospectus to reduce the amount of common stock we may offer and sell under the sales agreement. As of the date of this prospectus supplement, we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part. After giving effect to these limits and other amounts we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we may offer and sell from and after the date hereof shares of our common stock having an aggregate offering price of up to $8,066,607 from time to time in accordance with the terms of the sales agreement pursuant to this prospectus supplement and the Prior Prospectus, inclusive of the shares sold prior to the date hereof. If our public float increases such that we may sell additional amounts under the sales agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file a prospectus supplement prior to selling such additional amounts.
As of July 24, 2025, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $42,306,201, which we calculated based on 23,046,121 shares of outstanding common stock as of July 24, 2025, of which 20,943,664 shares were held by non-affiliates, and a price per share of $2.02, which was the closing price of our common stock on June 3, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell, pursuant to the registration statement of which this prospectus supplement and the Prior Prospectus form a part, securities with a value exceeding one-third of the aggregate market value of our outstanding common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our outstanding common stock held by non-affiliates remains below $75.0 million. During the 12 calendar months prior to and including the date of this prospectus supplement, we have offered or sold shares of our common stock having an aggregate purchase price of $35,460 pursuant to General Instruction I.B.6 of Form S-3.
Our common stock is listed on The Nasdaq Capital Market under the trading symbol “RNTX.” On July 28, 2025, the last sale price of our common stock as reported on The Nasdaq Capital Market was $1.41 per share.
Investing in our common stock involves certain risks. See “Risk Factors” beginning on page SA-6 of the Prior Prospectus and in the documents incorporated by reference in the Prior Prospectus for a discussion of the factors you should carefully consider before deciding to invest in our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prior Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
July 30, 2025
Source:
FAQ
How much common stock can Rein Therapeutics (RNTX) now sell under its ATM program?
Why was the ATM capacity reduced?
How many shares has RNTX sold so far through the ATM?
What is RNTX鈥檚 current share price and market cap?
Will future ATM sales dilute existing shareholders?
